Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-Guided First-Line Treatment for Advanced Leiomyosarcoma
NCT07405346Enrolling by invitation
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial in leiomyosarcoma (LMS). Primary endpoint: Objective Response Rate up to 2 years. Started Mar 2026; status: enrolling by invitation.
02
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT07405346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405346.